Gilead Sciences, Inc. (TSX:GILD)

Market Cap	248.12B +50.5%
Revenue (ttm)	40.51B +2.8%
Net Income	11.30B +6,336.5%
EPS	8.95 +6,514.1%
Shares Out	n/a
PE Ratio	21.96
Forward PE	17.97
Dividend	0.49 (1.63%)
Ex-Dividend Date	Dec 15, 2025

Volume	402
Average Volume	4,206
Open	29.50
Previous Close	29.51
Day's Range	29.50 - 29.96
52-Week Range	20.08 - 29.96
Beta	n/a
RSI	77.63
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD